LUCA Science
Tokyo
About LUCA Science
LUCA Science is at the forefront of a new kind of mitochondrial therapy that aims to restore cellular bioenergetics in malfunctioning or damaged tissues and organs. Using our patented iMIT technology, LUCA Science is creating a novel platform of highly functional mitochondria. We could boost bioenergetics and restore normal activities by supplying intact and functional mitochondria to the affected tissues. The utilization of mitochondria as a biopharmaceutical agent would be groundbreaking for treating a wide range of unmet medical needs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $39.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jun 2022)
- Website: luca-science.com
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/luca-science-34054 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.